Celgene gets positive NICE opinion for Otezla in plaque psoriasis
US biotech firm Celgene (Nasdaq: CELG) announced today that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral Otezla(apremilast) following a positive final appraisal determination from the National Institute for Health and Care Excellence (NICE).
The decision, which confirms a draft guidance issued in August this year that reversed a previous negative opinion, is the conclusion of a NICE Rapid Review, and ensures patients in England and Wales join those in Scotland, who have been benefitting from access to Otezla since it was recommended by the Scottish Medicines Consortium (SMC) in June 2015.
Psoriasis, an inflammatory disease of the skin,is estimated to affect around 960,000 adults in the UK.Despite there being a number of effective treatment options available for psoriasis, evidence suggests that a substantial proportion of people with psoriasis recognize the need for new treatments.7
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze